Comparison of prediction methods for treatment continuation of antipsychotics in children and adolescents with schizophrenia.

IF 6.6 2区 医学 Q1 PSYCHIATRY
Soo Min Jeon, Jaehyeong Cho, Dong Yun Lee, Jin-Won Kwon
{"title":"Comparison of prediction methods for treatment continuation of antipsychotics in children and adolescents with schizophrenia.","authors":"Soo Min Jeon,&nbsp;Jaehyeong Cho,&nbsp;Dong Yun Lee,&nbsp;Jin-Won Kwon","doi":"10.1136/ebmental-2021-300404","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>There is little evidence for finding optimal antipsychotic treatment for schizophrenia, especially in paediatrics. To evaluate the performance and clinical benefit of several prediction methods for 1-year treatment continuation of antipsychotics.</p><p><strong>Design and settings: </strong>Population-based prognostic study conducting using the nationwide claims database in Korea.</p><p><strong>Participants: </strong>5109 patients aged 2-18 years who initiated antipsychotic treatment with risperidone/aripiprazole for schizophrenia between 2010 and 2017 were identified.</p><p><strong>Main outcome measures: </strong>We used the conventional logistic regression (LR) and common six machine-learning methods (least absolute shrinkage and selection operator, ridge, elstic net, randomforest, gradient boosting machine, and superlearner) to derive predictive models for treatment continuation of antipsychotics. The performance of models was assessed using the Brier score (BS), area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC). The clinical benefit of applying these models was also evaluated by comparing the treatment continuation rate between patients who received the recommended medication by models and patients who did not.</p><p><strong>Results: </strong>The gradient boosting machine showed the best performance in predicting treatment continuation for risperidone (BS, 0.121; AUROC, 0.686; AUPRC, 0.269). Among aripiprazole models, GBM for BS (0.114), SuperLearner for AUROC (0.688) and random forest for AUPRC (0.317) showed the best performance. Although LR showed lower performance than machine learnings, the difference was negligible. Patients who received recommended medication by these models showed a 1.2-1.5 times higher treatment continuation rate than those who did not.</p><p><strong>Conclusions: </strong>All prediction models showed similar performance in predicting the treatment continuation of antipsychotics. Application of prediction models might be helpful for evidence-based decision-making in antipsychotic treatment.</p>","PeriodicalId":12233,"journal":{"name":"Evidence Based Mental Health","volume":null,"pages":null},"PeriodicalIF":6.6000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/e3/ebmental-2021-300404.PMC9811082.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence Based Mental Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/ebmental-2021-300404","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: There is little evidence for finding optimal antipsychotic treatment for schizophrenia, especially in paediatrics. To evaluate the performance and clinical benefit of several prediction methods for 1-year treatment continuation of antipsychotics.

Design and settings: Population-based prognostic study conducting using the nationwide claims database in Korea.

Participants: 5109 patients aged 2-18 years who initiated antipsychotic treatment with risperidone/aripiprazole for schizophrenia between 2010 and 2017 were identified.

Main outcome measures: We used the conventional logistic regression (LR) and common six machine-learning methods (least absolute shrinkage and selection operator, ridge, elstic net, randomforest, gradient boosting machine, and superlearner) to derive predictive models for treatment continuation of antipsychotics. The performance of models was assessed using the Brier score (BS), area under the receiver operating characteristic curve (AUROC) and area under the precision-recall curve (AUPRC). The clinical benefit of applying these models was also evaluated by comparing the treatment continuation rate between patients who received the recommended medication by models and patients who did not.

Results: The gradient boosting machine showed the best performance in predicting treatment continuation for risperidone (BS, 0.121; AUROC, 0.686; AUPRC, 0.269). Among aripiprazole models, GBM for BS (0.114), SuperLearner for AUROC (0.688) and random forest for AUPRC (0.317) showed the best performance. Although LR showed lower performance than machine learnings, the difference was negligible. Patients who received recommended medication by these models showed a 1.2-1.5 times higher treatment continuation rate than those who did not.

Conclusions: All prediction models showed similar performance in predicting the treatment continuation of antipsychotics. Application of prediction models might be helpful for evidence-based decision-making in antipsychotic treatment.

Abstract Image

儿童和青少年精神分裂症患者抗精神病药物持续治疗预测方法的比较。
目的:寻找精神分裂症的最佳抗精神病药物的证据很少,特别是在儿科。评价几种预测抗精神病药物持续治疗1年的方法的效果和临床获益。设计和设置:使用韩国全国索赔数据库进行基于人群的预后研究。参与者:在2010年至2017年期间,5109名2-18岁的精神分裂症患者开始使用利培酮/阿立哌唑抗精神病治疗。主要结果测量:我们使用传统的逻辑回归(LR)和常见的六种机器学习方法(最小绝对收缩和选择算子、脊线、弹性网、随机森林、梯度增强机和超级学习者)来推导抗精神病药物治疗持续的预测模型。采用Brier评分(BS)、受试者工作特征曲线下面积(AUROC)和精确召回率曲线下面积(AUPRC)对模型的性能进行评价。应用这些模型的临床效益也通过比较接受模型推荐药物的患者和未接受模型推荐药物的患者的治疗延续率来评估。结果:梯度增强机预测利培酮持续治疗效果最佳(BS, 0.121;AUROC 0.686;AUPRC, 0.269)。在阿立哌唑模型中,GBM模型对BS(0.114)、SuperLearner模型对AUROC(0.688)和随机森林模型对AUPRC(0.317)表现最好。虽然LR的表现不如机器学习,但差异可以忽略不计。接受这些模型推荐药物治疗的患者的治疗持续率比未接受推荐药物治疗的患者高1.2-1.5倍。结论:所有预测模型在预测抗精神病药物持续治疗方面表现相似。预测模型的应用可能有助于抗精神病药物治疗的循证决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
18.10
自引率
7.70%
发文量
31
期刊介绍: Evidence-Based Mental Health alerts clinicians to important advances in treatment, diagnosis, aetiology, prognosis, continuing education, economic evaluation and qualitative research in mental health. Published by the British Psychological Society, the Royal College of Psychiatrists and the BMJ Publishing Group the journal surveys a wide range of international medical journals applying strict criteria for the quality and validity of research. Clinicians assess the relevance of the best studies and the key details of these essential studies are presented in a succinct, informative abstract with an expert commentary on its clinical application.Evidence-Based Mental Health is a multidisciplinary, quarterly publication.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信